---
title: "Neurocrine Biosciences, Inc. (NBIX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NBIX.US.md"
symbol: "NBIX.US"
name: "Neurocrine Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T05:58:59.599Z"
locales:
  - [en](https://longbridge.com/en/quote/NBIX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NBIX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NBIX.US.md)
---

# Neurocrine Biosciences, Inc. (NBIX.US)

## Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.neurocrine.com](https://www.neurocrine.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.22)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 16 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 28.59% |  |
| Net Profit YoY | 118.64% |  |
| P/B Ratio | 4.64 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15812494805.11 |  |
| Revenue | 3102400000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 22.50% | A |
| Profit Margin | 21.55% | A |
| Gross Margin | 61.94% | A |
| Revenue YoY | 28.59% | A |
| Net Profit YoY | 118.64% | A |
| Total Assets YoY | 33.04% | A |
| Net Assets YoY | 34.38% | A |
| Cash Flow Margin | 129.18% | B |
| OCF YoY | 28.59% | A |
| Turnover | 0.72 | B |
| Gearing Ratio | 30.55% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Neurocrine Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "28.59%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "118.64%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.64",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "15812494805.11",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3102400000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "22.50%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "21.55%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "61.94%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "28.59%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "118.64%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "33.04%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "34.38%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "129.18%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "28.59%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.72",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "30.55%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 23.22 | 40/386 | 40.40 | 35.30 | 27.58 |
| PB | 4.56 | 311/386 | 5.12 | 4.79 | 4.09 |
| PS (TTM) | 5.00 | 108/386 | 5.50 | 5.17 | 4.65 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **27**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 19 | 70% |
| Overweight | 4 | 15% |
| Hold | 4 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 154.36 |
| Highest Target | 250.65 |
| Lowest Target | 140.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NBIX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NBIX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NBIX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NBIX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**